Windlas Biotech Ltd reports Q2 FY27 revenue of ₹263.91 crore, up 18.7% year on year, and appoints Hitesh Windlass Chairman
- Q2 FY27 net profit was ₹18.05 crore, up 1.4% year on year; calculated EBITDA-based operating margin was 11.1%.
- Revenue rose 6.4% sequentially; net profit increased 2.3% sequentially.
- The limited review conclusion was unmodified; the auditor drew attention to the US subsidiary’s dissolution and the absence of consolidated financial statements from April 1, 2026.
- Ashok Kumar Windlass resigned as director and was appointed Founder President/Senior Management Personnel from November 6, subject to shareholder approval.